About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 704 record(s)
Req # A-2019-000536
All documents regarding the approval of Crest Gum Detoxify from the Licensed Natural Health Products Database.Organization: Health Canada
January 2023
Req # A-2020-000178
The patient consent forms, clinical trial protocols, and investigator brochures/information (including amendments to any of the foregoing) for the following clinical trials included in: 1. Title: Multicenter Study of the Safety and Efficacy of the Human Anti-Tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis. 2. Title: Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy. 3. Title: Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis. 4. Title: A Phase II Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn’s Disease. 5. Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects With Crohn’s Disease, Open Label Extension.Organization: Health Canada
January 2023
Req # A-2021-000769
All communitcations between June 1, 2021 and August 13, 2021 that reference Alberta’s decision to lift all restrictions and reopen for summer. All communications strategies about Alberta’s decision between June 1 and August 13 around declaring the pandemic over and lifting all restrictions.Organization: Health Canada
January 2023
Req # A-2021-000997
All internal Health Canada (HC) communications between 1 Jan 2021 and 25 Sep 2021 regarding ivermectin with respect to SARS-CoV2 and COVID-19 in any capacity.Organization: Health Canada
January 2023
Req # A-2021-001961
All documents submitted to Health Canada pursuant to the regulatory review that resulted in the Regulatory Decision Summary (ages 5-11) dated 2021-11-19 for the Comirnaty Vaccine. The full regulatory review decision from which the summary was generated. See https://covid-vaccine.canada.ca/comirnaty/product-details.Organization: Health Canada
January 2023
Req # A-2021-001966
All documents submitted by BioNTech Manufacturing Company GmbH or Pfizer as part of the regulatory review that resulted in the Regulatory Decision Summary dated 2021-11-09 for the Comirnaty Vaccine. The full regulatory review decision from which the summary was generated. See https://covid-vaccine.canada.ca/comirnaty/product-details.Organization: Health Canada
January 2023
Req # A-2022-000298
All submissions made by Syqe Medical Ltd (company ID 150906) with respect to Class II Licence No. 105910 including but not limited to Syqe Inhaler (device identifier SYQ000101), Syqe Mouthpiece (device identifier SYQ000102), Syqe Wall adapter and Cable (device identifier SYQ000106) and Syqe cartridge ( device identifier SYQ000103).Organization: Health Canada
January 2023
Req # A-2022-000445
All records that discuss a delay in critical cancer diagnoses, treatment or similar as a direct consequence of COVID-19.Organization: Health Canada
January 2023
Req # A-2022-000516
Access to information request for the following companies: Medego Immobilier Inc. (NEQ: 1167724245) 12 De Richelieu Street, Chambly, Quebec, J3L 2B9, Chirurgie Dix30 Inc. (NEQ: 1169096287) 220-9090 Leduc Blvd., Brossard, Quebec, J4Y 0E2. As part of due diligence on the above-mentioned companies, we would like certain information regarding the status of these companies' records with your organization.Organization: Health Canada
January 2023
Req # A-2022-000524
All emails regarding the Subway comments after the All Staff meeting, as well as all the follow-up emails regarding the Subway comments, as well as all emails regarding the memes and comments being circulated since the All Staff meeting.Organization: Health Canada
January 2023